Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Professional Essentials · True Rheumatic Emergencies · Free · No registration

Mesenteric ischemia & vasculitic acute abdomen

Recognize threatened bowel, arrange urgent vascular imaging and coordinate reperfusion, surgery and disease-specific immune treatment.

Clinically reviewed: October 4, 2026 · Free to read · English

1. Recognize bowel threat before assigning a cause

Acute mesenteric ischemia (AMI) is a time-critical threat to bowel viability. In a patient with vasculitis, lupus or antiphospholipid syndrome, severe unexplained abdominal pain requires urgent assessment for ischemia alongside infection, obstruction, perforation and bleeding. A rheumatic diagnosis does not establish that the current episode is inflammatory. Ask about abrupt onset, previous postprandial pain or weight loss, atrial fibrillation, prior thrombosis and recent interruption of anticoagulation. These histories help identify plausible mechanisms but do not replace emergency evaluation or exclude overlapping inflammatory and thrombotic disease.

Pain disproportionate to examination is an important warning, but its absence is not reassuring. Early ischemia may produce little tenderness; rectal bleeding can be absent. In a sedated or critically ill patient, new distension, feeding intolerance, worsening acidosis or rising circulatory support may be the presenting concern.

Peritoneal signs, perforation or deteriorating perfusion require immediate surgical and critical-care assessment. Do not wait for a positive autoantibody, rising lactate or response to glucocorticoids. If bowel exploration is already necessary, imaging must not delay it. Assign a clinician to coordinate emergency surgery, vascular intervention, radiology and rheumatology rather than waiting for serial specialty opinions.

Recognizing threatened bowel → Professional access required

2. Stabilize and obtain the right imaging

Keep the patient fasting, obtain IV access, monitor circulation and provide analgesia. Replace fluid according to perfusion and cardiac/renal tolerance; correct important electrolyte abnormalities. Gastric decompression may be needed for vomiting, ileus or marked distension. Necessary vasopressor support requires coordinated critical-care management, including attention to the low-flow state.

Send blood count, platelets, kidney function, electrolytes, coagulation studies, blood gas/lactate and blood grouping. Add cultures and targeted tests for competing diagnoses. Obtain these in parallel with definitive assessment. No laboratory result can safely authorize a delay in suspected AMI.

The 2025 ESVS guideline supports urgent contrast-enhanced CTA with arterial and venous assessment, including in renal impairment. Tell radiology explicitly that mesenteric ischemia is suspected. A noncontrast scan or routine venous-phase CT may leave the arterial question unanswered; oral contrast should not postpone imaging.

The WSES guideline recommends early broad-spectrum antibiotics for AMI because bowel-barrier failure can precede obvious perforation. Use local intra-abdominal protocols and reassess against the established mechanism, cultures and source control. This is not an antibiotic rule for every episode of lupus abdominal pain.

Immediate assessment and routing → Professional access required

3. Interpret vessels, bowel and physiology together

Ask whether CTA adequately shows mesenteric arterial inflow, venous drainage, bowel enhancement and complications. Patent proximal vessels do not exclude distal disease, non-occlusive ischemia or inflammatory small-vessel injury. Pneumatosis or portal venous gas increases concern in context but does not independently prove irreversible necrosis.

ESVS advises against using a single lactate or D-dimer measurement to confirm or exclude AMI. A prospective 67-patient study associated organ failure, elevated lactate and bowel dilation with irreversible injury. It supports integrated assessment; its single-center model does not provide clearance when one feature is absent, particularly for mechanisms sparsely represented in that cohort.

In SLE, bowel-wall edema, layered enhancement and engorged mesenteric vessels can support lupus enteritis, but these findings are nonspecific. The Janssens series and literature review documents this diagnostic overlap. Low complement adds disease context without distinguishing inflammation from thrombosis, infection or infarction. Persistent concern after a reportedly negative study warrants direct radiology/surgical review of its adequacy and the evolving clinical picture.

CTA interpretation and diagnostic traps → Professional access required

4. Treat the vascular mechanism and assess viability

Arterial occlusion requires an urgent reperfusion decision. Endovascular, open and hybrid approaches depend on anatomy, bowel injury, physiological state and local capability. The goal is to restore flow while identifying bowel that requires resection and preserving viable length. Successful vessel recanalization alone does not establish intestinal recovery.

The 2025 AMESI prospective observational substudy found that patients selected for initial surgery were more severely ill; treatment comparisons were substantially affected by selection. It did not establish a symptom-duration threshold guaranteeing success with endovascular treatment alone. These data support individualized multidisciplinary decisions rather than a universal procedure rule.

For mesenteric venous thrombosis, therapeutic heparin is first-line treatment when not contraindicated. Review bleeding, platelets, prior heparin-induced thrombocytopenia and procedural needs. Peritonitis or clinical deterioration still requires urgent bowel assessment. In non-occlusive mesenteric ischemia, restore perfusion and treat the precipitant; selected centers may consider catheter-directed vasodilators, with limited evidence and hypotension risk. Neither anticoagulation nor vasodilator treatment substitutes for removal of necrotic bowel.

Arterial, venous and low-flow mechanisms → Professional access required

5. Add disease-specific immune treatment

When active vasculitis is strongly suspected, plan immune treatment alongside infection evaluation, reperfusion and surgical assessment. A steroid trial must not become a diagnostic waiting period. Conversely, necessary surgical consultation should not leave convincing life-threatening inflammation untreated indefinitely.

For severe systemic polyarteritis nodosa, ACR/Vasculitis Foundation guidance conditionally favors initial IV pulse glucocorticoids and cyclophosphamide with glucocorticoids over glucocorticoid monotherapy. Evidence is limited. The guideline excludes hepatitis B-associated PAN, which requires a different specialist strategy. Do not transfer a PAN regimen automatically to every abdominal vasculitis.

Uncomplicated lupus enteritis often responds to glucocorticoids, but evidence is observational and recurrence is possible. Severe disease or unreliable absorption may favor IV administration; additional immunosuppression depends on refractory or recurrent disease and other organ involvement. Recurrent pain still needs a fresh assessment for thrombosis, infection and structural injury.

For severe SLE vasculitis, the 2025 ACR guideline conditionally favors IV cyclophosphamide or anti-CD20 therapy with glucocorticoids. For life-threatening vasculitis, including mesenteric involvement, it conditionally supports adding plasma exchange and/or IVIG. Very-low-certainty evidence and patient-specific risks require specialist judgment; these adjuncts do not replace bowel rescue.

Disease-specific treatment boundaries → Professional access required

6. Reassess recovery and document the onward plan

Follow abdominal findings, perfusion, support requirements, lactate/acid-base trends, kidney function and bleeding together. Less pain with increasing distension or worsening shock is not recovery. Reassess immediately rather than waiting for a routine laboratory interval. The surgical team may plan a second look when viability remains uncertain; deterioration can require earlier intervention.

At handoff, record symptom timing, examination limitations, actual CTA findings, treatment times and the clinician responsible for the next decision. Transfer images as well as reports. State whether the patient has received anticoagulation, antibiotics or immunosuppression and identify pending results. A provisional label such as “lupus enteritis” must travel with the evidence supporting it and the alternatives that remain unresolved. Where local vascular capability is absent, agree a specific transfer plan without delaying necessary emergency source control.

After stabilization, reconcile operative findings, pathology and the final mechanism. Plan anticoagulation according to the thrombotic disorder and bleeding risk, vascular surveillance after intervention, and immune-treatment monitoring when indicated. Following substantial resection, involve nutrition and intestinal rehabilitation. Document remaining bowel anatomy and explain that recurrent severe pain, vomiting, bleeding or systemic deterioration needs urgent reassessment.

Reassessment and handoff → Professional access required

Selected sources

Clinical review: October 4, 2026. This independent overview accompanies the full professional emergency module.

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Rheumatology